New insights into addressing antibiotic resistance

Reducing antibiotic use by avoiding catheter-associated urinary tract infections (CAUTIs)
Antibiotic Resistance: The CAUTI Connection

The unnecessary use and misuse of antibiotics has led to a significant healthcare problem – antibiotic resistance.

- More than 70% of the bacteria that cause nosocomial (hospital-acquired) infections are resistant to at least one of the drugs most commonly used to treat them.

- Patients infected with drug-resistant organisms are more likely to have longer hospital stays and require more treatment with second- or third-choice drugs that may be less effective, more toxic, and/or more expensive.

Catheter-associated urinary tract infections (CAUTIs) contribute to the problem of antibiotic resistance:

- CAUTIs comprise the largest institutional reservoir of antibiotic-resistant pathogens.

- Patients presenting with asymptomatic bacteriuria are nevertheless treated with antibiotics 71% of the time and intravenous antibiotics 28% of the time.

- Patients presenting with symptomatic CAUTI are treated with intravenous antibiotics 49% of the time.

Reduce antibiotic use by avoiding catheter-associated urinary tract infections (CAUTIs)

The use of anti-infective urinary catheters is recommended for addressing the public health threat of antibiotic resistance.
Addressing Antibiotic Resistance with Proven Technology

The Bardex® I.C. Anti-Infective Foley Catheter uses Bacti-Guard® silver alloy coating technology, which is clinically proven to reduce catheter-associated urinary tract infections.2,5,6

Standardizing on the Bardex® I.C. Anti-Infective Foley Catheter with Bacti-Guard® silver alloy coating and Bard® Hydrogel reduces antibiotic use

By adopting infection control technologies, such as the Bardex® I.C. Anti-Infective Foley Catheter with Bacti-Guard® silver alloy coating, antibiotic use may be significantly minimized.

- Antibiotic usage, targeted at UTIs, is reduced by over 40% (RR less than 0.6)3,7
- IV antibiotic usage, targeted at UTIs, is reduced by over 50% (RR less than 0.5)9

Reduce Nosocomial UTIs with the Bardex® I.C. Anti-Infective Foley Catheter

Use of the Bardex® I.C. Foley catheter is clinically proven to decrease the incidence of CAUTI by 26% to 47%2,5,6

Recommended by a federal task force – CDC, FDA, and NIH – to resist-resistant pathogens.9
Address Antibiotic Resistance by Avoiding Infection

- Hospital-acquired urinary tract infections (UTIs) account for over 40% of all hospital-acquired infections.¹

- Catheter-associated UTIs (CAUTIs) comprise the largest institutional reservoir of antibiotic-resistant pathogens.²

- Use of the Bardex® I.C. Anti-Infective Foley Catheter with Bacti-Guard®* silver alloy coating and Bard® Hydrogel is clinically proven to decrease the incidence of CAUTIs by 26% to 47%.²,⁵,⁶

- Reduce antibiotic usage and address antibiotic resistance by standardizing on the Bardex® I.C. Anti-Infective Foley Catheter with Bacti-Guard®* silver alloy coating and Bard® Hydrogel.³,⁷,⁸,⁹

- Use of the Bardex® I.C. Anti-Infective Foley Catheter with Bacti-Guard®* silver alloy coating and Bard® Hydrogel does not select for CAUTIs caused by silver-resistant organisms.²

References


www.bardmedical.com

Bard Medical Division
C.R. Bard, Inc.
8195 Industrial Blvd.
Covington, GA 30014
800-526-4455

Please consult product label and insert for any indications, contraindications, hazards, warnings, cautions, and directions for use.

*The Foley catheters in the Bardex® I.C. System contain Bacti-Guard® silver alloy coating, licensed from Adhesive Technology (International) Licensing, B.V.

Bard and Bardex are registered trademarks and the I.C. logo is a trademark of C.R. Bard, Inc. or an affiliate.

Bacti-Guard is a registered trademark of Adhesive Technology (International) Licensing, B.V.

©2004 C.R. Bard, Inc. All Rights Reserved.